Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks
NCT ID: NCT04739059
Last Updated: 2026-01-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
171 participants
INTERVENTIONAL
2021-04-29
2025-11-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks
NCT04656418
Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab
NCT06806657
CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema
NCT05819775
Post Study Access of CSL312 (Garadacimab) for Pediatric Participants With Hereditary Angioedema Who Have Completed the CSL312_3003 Study
NCT07159464
A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)
NCT03712228
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CSL312
Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody administered subcutaneously
CSL312
Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CSL312
Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* \- Diagnosed with clinically confirmed C1-INH HAE
* \- Experienced ≥ 3 HAE attacks during the 3 months before Screening
* \- Participated in the Run-in Period for at least 1 month (CSL312-naïve subjects only)
* \- Experienced at least an average of 1 HAE attack per month during the Run-in Period
Exclusion Criteria
* \- Use of C1-INH products, androgens, antifibrinolytics or other small molecule medications for routine prophylaxis against HAE attacks at least 2 weeks before the first day of the Run-in Period
* \- Use of monoclonal antibodies such as lanadelumab (Takhzyro®) 3 months before the first day of the Run-in Period.
* \- Female subjects use estrogen-containing oral contraceptives or hormone replacement therapy within 4 weeks prior to screening
* \- Female or male subjects who are fertile and sexually active not using or not willing to use an acceptable method of contraception to avoid pregnancy during the study and for 30 days after receipt of the last dose of CSL312
* \- Pregnant, breastfeeding, or not willing to cease breastfeeding
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CSL Behring
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
CSL Behring
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Research Center of Alabama
Birmingham, Alabama, United States
Research Solutions of Arizona
Litchfield Park, Arizona, United States
Medical Research of Arizona
Scottsdale, Arizona, United States
Little Rock Allergy & Asthma Clinic
Little Rock, Arkansas, United States
Donald S. Levy M.D.
Orange, California, United States
Raffi Tachdjian MD, Inc.
Santa Monica, California, United States
Allergy & Asthma Clinical Research
Walnut Creek, California, United States
Institute for Asthma and Allergy PC
Chevy Chase, Maryland, United States
Bernstein Clinical Research Center, LLC
Cincinnati, Ohio, United States
PennState Health Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States
AARA Research Center
Dallas, Texas, United States
Campbelltown Hospital / Western Sydney University
Campbelltown, New South Wales, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Fiona Stanley Hospital, Department of Clinical Immunology
Murdoch, Western Australia, Australia
University of Alberta - Research Transition Facility
Edmonton, Alberta, Canada
McMaster University
Hamilton, Ontario, Canada
Ottawa Allergy Research Corp
Ottawa, Ontario, Canada
Gordon Sussman Clinical Research
Toronto, Ontario, Canada
Montreal Clinical Research Institute
Montreal, Quebec, Canada
University hospital St. Anna Ustav klinicke imunologie a alergologie, Fakultní nemocnice u sv. Anny v Brně
Brno, , Czechia
University Hospital Motol
Prague, , Czechia
Charité - Universitätsmedizin Berlin
Berlin, , Germany
Universitätsklinikum Frankfurt
Frankfurt, , Germany
Johannes Gutenberg-Universität KöR, Hautklinik und Poliklinik der Universitätsmedizin, Clinical Research Center
Mainz, , Germany
HZRM Haemophilie Zentrum Rhein Main GmbH
Mörfelden-Walldorf, , Germany
The University of Hong Kong, Queen Mary Hospital
Hong Kong, , Hong Kong
Semmelweis Egyetem Altalanos Orvostudományi Kar Belgyógyászati és Hematológiai Klinika
Budapest, , Hungary
Barzilai University Medical Center
Ashkelon, , Israel
Koga Community Hospital
Shizuoka, Daikakuji Yaizu-shi, Japan
Mie University Hospital
Mie, Edobashi, Tsu-shi, Japan
Juntendo University Hospital
Tokyo, Hongo Bunkyo-ku, Japan
Saitama Medical Center
Saitama, Kamoda Kawagoe-shi, Japan
St. Marianna University School of Medicine Hospital
Kanagawa, Kawasaki-shi, Japan
Clover Hospital
Kanagawa, Kugenumaishigami, Fujisawa-shi, Japan
Saiyu Soka Hospital
Saitama, Matsubara Soka-shi, Japan
National Hospital Organization Disaster Medical Center
Tokyo, Midoricho, Tachikawa-shi, Japan
Saga University Hospital
Saga, Nebeshima, Saga-shi, Japan
Local Incorporated Administrative Agency Osaka City Hospital Organization Osaka City General Hospital
Miyakojima-ku, Osaka-shi, Japan
Amsterdam UMC, location AMC
Amsterdam, , Netherlands
Auckland City Hospital
Grafton, Auckland, New Zealand
NRC Institute of Immunology FMBA Russia
Moscow, , Russia
Hospital Universitari General de La Vall d'Hebron
Barcelona, , Spain
Hospital Gregorio Marañón, Servicio de Alergia
Madrid, , Spain
Taichung Veterans General Hospital
Taichung, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-003918-12
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CSL312_3002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.